Cormorant Asset Management as of Sept. 30, 2014
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 65 positions in its portfolio as reported in the September 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Puma Biotechnology (PBYI) | 24.9 | $121M | 508k | 238.57 | |
| Receptos | 9.6 | $47M | 749k | 62.11 | |
| Jazz Pharmaceuticals (JAZZ) | 3.3 | $16M | 100k | 160.56 | |
| Dyax | 3.1 | $15M | 1.5M | 10.12 | |
| Keryx Biopharmaceuticals | 2.8 | $14M | 1.0M | 13.75 | |
| Karyopharm Therapeutics (KPTI) | 2.8 | $14M | 385k | 34.94 | |
| Neurocrine Biosciences (NBIX) | 2.7 | $13M | 850k | 15.67 | |
| Arrowhead Research | 2.7 | $13M | 900k | 14.77 | |
| Acceleron Pharma | 2.5 | $12M | 400k | 30.24 | |
| BioCryst Pharmaceuticals (BCRX) | 2.2 | $11M | 1.1M | 9.78 | |
| Akebia Therapeutics (AKBA) | 1.8 | $8.9M | 400k | 22.13 | |
| Ovascience | 1.8 | $8.6M | 516k | 16.60 | |
| Tesaro | 1.7 | $8.1M | 300k | 26.92 | |
| Dex (DXCM) | 1.6 | $8.0M | 200k | 39.99 | |
| Bristol Myers Squibb (BMY) | 1.6 | $7.7M | 150k | 51.18 | |
| Omeros Corporation (OMER) | 1.4 | $7.0M | 548k | 12.72 | |
| Chimerix (CMRX) | 1.4 | $6.9M | 250k | 27.62 | |
| Synageva Biopharma | 1.4 | $6.9M | 100k | 68.78 | |
| Ultragenyx Pharmaceutical (RARE) | 1.4 | $6.8M | 120k | 56.60 | |
| Novavax | 1.3 | $6.3M | 1.5M | 4.17 | |
| Agios Pharmaceuticals (AGIO) | 1.3 | $6.1M | 100k | 61.35 | |
| Heron Therapeutics (HRTX) | 1.2 | $5.8M | 700k | 8.33 | |
| Ardelyx (ARDX) | 1.1 | $5.5M | 389k | 14.21 | |
| Acelrx Pharmaceuticals | 1.1 | $5.5M | 1.0M | 5.49 | |
| Ptc Therapeutics I (PTCT) | 1.1 | $5.5M | 125k | 44.01 | |
| Nektar Therapeutics (NKTR) | 1.1 | $5.4M | 450k | 12.07 | |
| Sangamo Biosciences (SGMO) | 1.1 | $5.4M | 500k | 10.79 | |
| China Biologic Products | 1.1 | $5.1M | 95k | 53.96 | |
| Portola Pharmaceuticals | 1.0 | $5.1M | 200k | 25.28 | |
| Eagle Pharmaceuticals (EGRX) | 1.0 | $5.1M | 400k | 12.65 | |
| Quotient | 1.0 | $4.7M | 500k | 9.43 | |
| Sorrento Therapeutics (SRNE) | 0.9 | $4.5M | 1.0M | 4.52 | |
| Alkermes (ALKS) | 0.9 | $4.3M | 100k | 42.87 | |
| Alnylam Pharmaceuticals (ALNY) | 0.8 | $3.9M | 50k | 78.10 | |
| Versartis | 0.8 | $3.8M | 200k | 18.99 | |
| Rockwell Medical Technologies | 0.8 | $3.7M | 400k | 9.14 | |
| Array BioPharma | 0.7 | $3.6M | 1.0M | 3.57 | |
| Immune Design | 0.7 | $3.5M | 200k | 17.66 | |
| Nanostring Technologies (NSTGQ) | 0.7 | $3.3M | 300k | 10.94 | |
| Kindred Biosciences | 0.7 | $3.2M | 350k | 9.25 | |
| Glycomimetics (GLYC) | 0.7 | $3.3M | 472k | 6.94 | |
| Clovis Oncology | 0.7 | $3.2M | 70k | 45.36 | |
| Kite Pharma | 0.6 | $2.9M | 100k | 28.50 | |
| Genvec | 0.6 | $2.8M | 1.3M | 2.08 | |
| Auspex Pharmaceuticals | 0.5 | $2.6M | 100k | 25.67 | |
| Galectin Therapeutics (GALT) | 0.5 | $2.3M | 450k | 5.03 | |
| Avalanche Biotechnologies In | 0.5 | $2.2M | 65k | 34.18 | |
| Recro Pharma | 0.4 | $2.1M | 700k | 2.96 | |
| Agenus | 0.4 | $2.0M | 650k | 3.11 | |
| Aquinox Pharmaceuticals | 0.4 | $2.0M | 300k | 6.66 | |
| Zs Pharma | 0.4 | $2.0M | 50k | 39.24 | |
| Alder Biopharmaceuticals | 0.4 | $1.9M | 150k | 12.68 | |
| Cerulean Pharma | 0.4 | $1.9M | 450k | 4.22 | |
| Celsus Therapeutics Plc sponsored adr ne | 0.3 | $1.5M | 245k | 6.10 | |
| Regulus Therapeutics | 0.3 | $1.4M | 200k | 6.83 | |
| Advaxis | 0.2 | $1.2M | 350k | 3.36 | |
| Cellectar Biosciences | 0.2 | $1.2M | 530k | 2.22 | |
| Applied Genetic Technol Corp C | 0.2 | $1.1M | 61k | 18.61 | |
| Agile Therapeutics | 0.2 | $1.1M | 150k | 7.30 | |
| Minerva Neurosciences | 0.2 | $1.1M | 175k | 6.05 | |
| Bristol-myers Squibb | 0.2 | $985k | 5.0k | 197.00 | |
| Curis | 0.2 | $846k | 600k | 1.41 | |
| Scynexis | 0.1 | $739k | 100k | 7.39 | |
| Cellectar Biosciences Inc *w exp 08/19/201 | 0.1 | $318k | 530k | 0.60 | |
| Sage Therapeutics (SAGE) | 0.1 | $315k | 10k | 31.50 |
